Conforma Therapeutics discovered and developed drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in protecting and supporting the growth of cancer cells across a range of tumor types, and which also play a role in tumor resistance to a number of cancer therapies.

Acquired by Biogen in May 2006.